1. Home
  2. GEOS vs MRUS Comparison

GEOS vs MRUS Comparison

Compare GEOS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEOS
  • MRUS
  • Stock Information
  • Founded
  • GEOS 1980
  • MRUS 2003
  • Country
  • GEOS United States
  • MRUS Netherlands
  • Employees
  • GEOS N/A
  • MRUS 260
  • Industry
  • GEOS Industrial Machinery/Components
  • MRUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GEOS Industrials
  • MRUS Health Care
  • Exchange
  • GEOS Nasdaq
  • MRUS Nasdaq
  • Market Cap
  • GEOS N/A
  • MRUS 2.7B
  • IPO Year
  • GEOS 1997
  • MRUS 2016
  • Fundamental
  • Price
  • GEOS $7.29
  • MRUS $39.60
  • Analyst Decision
  • GEOS
  • MRUS Strong Buy
  • Analyst Count
  • GEOS 0
  • MRUS 13
  • Target Price
  • GEOS N/A
  • MRUS $86.85
  • AVG Volume (30 Days)
  • GEOS 61.4K
  • MRUS 650.7K
  • Earning Date
  • GEOS 05-08-2025
  • MRUS 05-07-2025
  • Dividend Yield
  • GEOS N/A
  • MRUS N/A
  • EPS Growth
  • GEOS N/A
  • MRUS N/A
  • EPS
  • GEOS N/A
  • MRUS N/A
  • Revenue
  • GEOS $122,789,000.00
  • MRUS $36,133,000.00
  • Revenue This Year
  • GEOS N/A
  • MRUS $37.72
  • Revenue Next Year
  • GEOS N/A
  • MRUS $48.47
  • P/E Ratio
  • GEOS N/A
  • MRUS N/A
  • Revenue Growth
  • GEOS N/A
  • MRUS N/A
  • 52 Week Low
  • GEOS $7.02
  • MRUS $37.77
  • 52 Week High
  • GEOS $14.83
  • MRUS $61.61
  • Technical
  • Relative Strength Index (RSI)
  • GEOS 34.22
  • MRUS 32.49
  • Support Level
  • GEOS $7.37
  • MRUS $39.00
  • Resistance Level
  • GEOS $7.87
  • MRUS $45.44
  • Average True Range (ATR)
  • GEOS 0.31
  • MRUS 2.44
  • MACD
  • GEOS 0.06
  • MRUS -0.93
  • Stochastic Oscillator
  • GEOS 17.11
  • MRUS 5.51

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Share on Social Networks: